ArticleOne health (Amsterdam, Netherlands)2023
Underestimated economic and social burdens of non-Typhoidal Salmonella infections: The One Health perspective from Nigeria.
Article in One health (Amsterdam, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Isolation and identification of a chicken-derived Salmonella phage VB-SalS-XND03, Its biological characteristics and application effect against Salmonella infection in chicks.Poultry science · 2026Article
- Integrating Statistical and Machine-Learning Approaches forMicroorganisms · 2025Article
- Seven Years ofMicroorganisms · 2025Article
- Phenotypic and genotypic characterisation of Salmonella serovars from poultry in ilorin, Kwara state, Nigeria.BMC microbiology · 2025Article
- Salmonella prevalence and serovar distribution in reptiles: a systematic review and meta-analysis.Gut pathogens · 2025Article
- Genomic Diversity and Antibiotic Resistance ofMicroorganisms · 2025Article
- The rise of non-typhoidalFrontiers in microbiology · 2025Article
- Cost-effectiveness of One Health intervention to reduce risk of human exposure and infection with non-typhoidal salmonellosis (NTS) in Nigeria.One health (Amsterdam, Netherlands) · 2024Article
- Non-typhoidalInternational journal of veterinary science and medicine · 2024Article
- Prevention and Control of HumanInternational journal of food science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The non-typhoidal salmonellosis (NTS) is a pathogenic bacterial zoonosis with substantial but often under-appreciated public health impacts. The NTS is prevalent in poultry and humans in Nigeria, yet its economic and social burden have not been determined through any empirical study. To bridge the gap, we evaluated the impact of NTS in social and economic terms. Methods: Relevant population, economic and epidemiological data were retrieved from peer-reviewed publications, open sources and relevant authorities. Additional data were obtained through experts' opinions and field surveys. Using a customized and validated Microsoft Excel® tool, economic analysis was conducted. Results: Using the year 2020 reference point, the burden of NTS was 325,731 cases and a total of 1043 human deaths, at a disability-adjusted life year (DALYs) of 37,321. The cost associated with infection in humans was US$ 473,982,068. A total loss of US$ 456,905,311 was estimated in poultry including the direct value of animal loss, US$ 224,236,769, loss from salvage slaughter and culling, US$ 220,386,556, and value of foregone production, US$ 12,281,987. Interpretation: The outcomes of this important work provide empirical evidence to support informed decisions and investments in the control and eradication of human and poultry salmonellosis (NTS) in Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.